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and J. Reyes 
WE PREVIOUSLY identified rejection as the most 
significant risk factor for intestinal allograft surviv-
al. l The reported efficacy of dac1izumab (Zenapax. Hoff-
man-LaRoche) prophylaxis with solid organ transplanta-
tion2 triggered its use at our center as induction therapy for 
intestinal transplantation. 
MATERIALS AND METHODS 
Oaclizumab was used as prophylactic therapy for a total of 14 
consecutive patients who received primary intestinal transplanta-
tion under tacrolimus-based immunosuppression during the period 
from May 31,1998 to March 31, 1999. Of these, eight (57%) were 
isolated intestine. and six (43%) were liver/intestine. Eight were 
children and seven were female patients. Oaclizumab was given 
intravenously in a dose of I to 2 mg/kg body weight for a total of 
five doses. The first dose was administered within a few hours 
before surgery and the remaining four doses were given postoper-
atively at 2. 4. 6. and 8 weeks after transplantation. In only one 
recipient (isolated intestine). the drug was discontinued after the 
second dose because of unexplained coagulopathy and recurrent 
gastric bleeding. Ccllcept or imuran were given from the outset in 
nine recipients. 
All donors were cadaveric and ABO identical. and HLA match-
ing was random. 
No attempts were made to immunomodulate any of the grafts 
with antilymphoid antibody treatment. irradiation, or other modal-
ities, and six patients received donor bone marrow augmentation. 
The crossmatch was positive with dithiothreitol (OTT) in four cases 
(two intestine. two liver/intestine). The mean (SO) cold ischemia 
time was 9.7 ::!: 2.7 hours. Details of the donor/recipient operations. 
and bone marrow augmentation technique have been described 
elsewhere.3-5 The observation period was limited to the first 
postoperative year with August 30, 1999 being the date of last 
follow-up. 
Acute rejection was diagnosed by histopathologic examination of 
random and endoscopically guided multiple mucosal biopsies. The 
adopted diagnostic criteria have been described elsewhere." A new 
rejection episode was defined by documentation of new histologic 
changes. All of the rejection episodes were histologically docu-
mented and medically treated. OKT3 was used to treat steroid-
resistant rejection. 
RESULTS 
With a mean follow-up of 8.5 ~ 3.9 months. II (79%) 
recipients were alive with fully functioning grafts. The three 
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deaths (two liver/intestine, one isolated intestine) occurred 
at 4. 56. and 225 days after transplantation. The causes were 
primary graft failure, rejection. and renal failure. The 
primary failed liver/intestinal graft was given to a black 
pediatric recipient across a strong positive crossmatch 
(titer: 1:512). The I-year Kaplan-Meier TPN-free sur-
vival rate was 77%. Dac1izumab prophylaxis resulted in a 
significant reduction in the incidence of rejection during 
the study period. With a mean follow-up of 8.5 ~ 3.9 
months, only six (43%) recipients experienced at least 
one episode of acute rejection at a mean onset of 22 ~ 18 
days after transplantation. The incidence of rejection 
was 30% at 1 month, 55.6% at 3 months. and 43% at 
6 months, with a mean number of episodes/patient of 
0.4 ~ 0.7, 1.0 ~ 1.1, and 1.1 ~ 1.8, respectively. OKT3 
was used to treat steroid-resistant rejection in four (29%) 
recipients. 
CMV was reactivated in one (7%) recipient at 121 days 
after transplantation. and PTLD was diagnosed in another 
(7%) patient during postoperative week 7. Both cases were 
treated successfully with antiviral therapy and careful re-
duction in immunosuppression. 
The mean total hospital stay was 4.6 ~ 2.2 weeks with an 
ICU stay of 7.6 ~ 6.5 days. Graft function was restored and 
TPN was discontinued at a median time of 20 days (range 8 
to 35) from date of transplantation. 
DISCUSSION 
These preliminary data show that daclizumab is beneficial 
as an induction therapy for intestinal allograft recipients. 
The risk of rejection during the first 6 months was signifi-
cantly reduced with a relatively low incidence of opportu-
nistic infections and short initial hospital stay.l.4 In conclu-
sion, daclizumab prophylaxis is an effective therapy for 
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intestinal transplantation. However. its long-term therapeu-
tic and survival benefits have yet to he defined. 
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